Literature DB >> 17586865

The pharmacogenetics of methotrexate.

S L Hider1, I N Bruce, W Thomson.   

Abstract

Methotrexate (MTX) is a cornerstone of therapy for rheumatoid arthritis. However, it is not universally effective and up to one-third of patients fail to respond to treatment, either because of inefficacy or adverse events, although at present it is not possible to predict therapy response accurately. Pharmacogenetics is the study of variability in drug response due to heredity. MTX has a complex intracellular metabolism and acts via a number of key enzymes. This review critically appraises the studies of MTX pharmacogenetics and highlights the need for further work in this area.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17586865     DOI: 10.1093/rheumatology/kem147

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  23 in total

Review 1.  Immunosuppression in clinical practice: approaches to individualized therapy.

Authors:  Andrew Chan; Olaf Stüve; Nicolas von Ahsen
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

2.  Effect of thymidylate synthase (TYMS) gene polymorphisms with methotrexate treatment outcome in south Indian Tamil patients with rheumatoid arthritis.

Authors:  Niveditha Muralidharan; Durga P Misra; Vikramraj K Jain; Vir Singh Negi
Journal:  Clin Rheumatol       Date:  2017-03-27       Impact factor: 2.980

3.  Nonassociation of homocysteine gene polymorphisms with treatment outcome in South Indian Tamil Rheumatoid Arthritis patients.

Authors:  Niveditha Muralidharan; Reena Gulati; Durga Prasanna Misra; Vir S Negi
Journal:  Clin Exp Med       Date:  2017-08-18       Impact factor: 3.984

4.  Alterations in the expression pattern of MTHFR, DHFR, TYMS, and SLC19A1 genes after treatment of laryngeal cancer cells with high and low doses of methotrexate.

Authors:  Ana Lívia Silva Galbiatti; Rodrigo Castro; Heloisa Cristina Caldas; João Armando Padovani; Erika Cristina Pavarino; Eny Maria Goloni-Bertollo
Journal:  Tumour Biol       Date:  2013-07-10

5.  Cardiovascular events are not associated with MTHFR polymorphisms, but are associated with methotrexate use and traditional risk factors in US veterans with rheumatoid arthritis.

Authors:  Lisa A Davis; Grant W Cannon; Lauren F Pointer; Leah M Haverhals; Roger K Wolff; Ted R Mikuls; Andreas M Reimold; Gail S Kerr; J Steuart Richards; Dannette S Johnson; Robert Valuck; Allan Prochazka; Liron Caplan
Journal:  J Rheumatol       Date:  2013-04-01       Impact factor: 4.666

6.  Population distribution of methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C risk alleles for methotrexate toxicity in Israel.

Authors:  Edna Efrati; Hela Elkin; Sagi Nahum; Norberto Krivoy
Journal:  Rheumatol Int       Date:  2012-07-31       Impact factor: 2.631

7.  Effect of folic acid on methotrexate induction of sulfotransferases in rats.

Authors:  Sangita Maiti Dutta; Smarajit Maiti; Guangping Chen
Journal:  Drug Metab Lett       Date:  2008-04

8.  Survival and risk of relapse of acute lymphoblastic leukemia in a Mexican population is affected by dihydrofolate reductase gene polymorphisms.

Authors:  Yazmín Gómez-Gómez; Jorge Organista-Nava; Mónica Virginia Saavedra-Herrera; Ana Bertha Rivera-Ramírez; Marco Antonio Terán-Porcayo; Luz Del Carmen Alarcón-Romero; Berenice Illades-Aguiar; Marco Antonio Leyva-Vázquez
Journal:  Exp Ther Med       Date:  2012-01-09       Impact factor: 2.447

9.  Methotrexate and 5-aminoimidazole-4-carboxamide riboside exert synergistic anticancer action against human breast cancer and hepatocellular carcinoma.

Authors:  Xiao-liang Cheng; Tian-yan Zhou; Bo Li; Meng-yao Li; Liang Li; Zai-quan Li; Wei Lu
Journal:  Acta Pharmacol Sin       Date:  2013-04-22       Impact factor: 6.150

10.  Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms.

Authors:  R B Warren; R L Smith; E Campalani; S Eyre; C H Smith; J N W N Barker; J Worthington; C E M Griffiths
Journal:  Br J Dermatol       Date:  2008-10-25       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.